Bifogade filer
Kurs
-1,27%
Likviditet
1,12 MSEK
Kalender
Est. tid* | ||
2025-05-13 | N/A | X-dag ordinarie utdelning ACUC 0.00 SEK |
2025-05-12 | N/A | Årsstämma |
2025-05-08 | - | Kvartalsrapport 2025-Q1 |
2025-02-21 | - | Bokslutskommuniké 2024 |
2024-12-19 | - | Extra Bolagsstämma 2024 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-08-23 | - | Kvartalsrapport 2024-Q2 |
2024-06-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2024-06-04 | - | Årsstämma |
2024-04-26 | - | Kvartalsrapport 2024-Q1 |
2024-02-16 | - | Bokslutskommuniké 2023 |
2023-11-30 | - | Kvartalsrapport 2023-Q3 |
2023-10-02 | - | Extra Bolagsstämma 2023 |
2023-08-31 | - | Kvartalsrapport 2023-Q2 |
2023-05-05 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2023-05-04 | - | Årsstämma |
2023-04-28 | - | Kvartalsrapport 2023-Q1 |
2023-02-24 | - | Bokslutskommuniké 2022 |
2022-11-11 | - | Kvartalsrapport 2022-Q3 |
2022-08-12 | - | Kvartalsrapport 2022-Q2 |
2022-05-06 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2022-05-04 | - | Årsstämma |
2022-04-28 | - | Kvartalsrapport 2022-Q1 |
2022-02-24 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-11 | - | Kvartalsrapport 2021-Q2 |
2021-04-29 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2021-04-28 | - | Årsstämma |
2021-04-28 | - | Kvartalsrapport 2021-Q1 |
2021-02-18 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-05-13 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2020-05-12 | - | Årsstämma |
2020-05-12 | - | Kvartalsrapport 2020-Q1 |
2020-02-25 | - | Bokslutskommuniké 2019 |
2019-11-19 | - | Kvartalsrapport 2019-Q3 |
2019-08-16 | - | Kvartalsrapport 2019-Q2 |
2019-05-17 | - | Kvartalsrapport 2019-Q1 |
2019-04-26 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2019-04-25 | - | Årsstämma |
2019-02-13 | - | Bokslutskommuniké 2018 |
2018-11-22 | - | Kvartalsrapport 2018-Q3 |
2018-08-31 | - | Kvartalsrapport 2018-Q2 |
2018-04-25 | - | Kvartalsrapport 2018-Q1 |
2018-03-22 | - | X-dag ordinarie utdelning ACUC 0.00 SEK |
2018-03-21 | - | Årsstämma |
2018-02-06 | - | Bokslutskommuniké 2017 |
2017-11-09 | - | Kvartalsrapport 2017-Q3 |
2017-08-30 | - | Kvartalsrapport 2017-Q2 |
2017-05-15 | - | Kvartalsrapport 2017-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Medicinteknik |
The pharmaceutical company AcuCort has received a renewed marketing authorisation for its medicinal product Zeqmelit® from the Norwegian Medical Products Agency (Direktoratet for medisinske produkter), Norway's equivalent of the Swedish Medical Products Agency. The decision grants approval without a time limitation.
AcuCort was first granted a marketing authorisation for Zeqmelit® in Norway in 2022. That approval was time-limited, which is standard for new medicines. Following an application for renewal, the Norwegian Medical Products Agency has now granted an extended marketing authorisation for the Norwegian market, this time without a time restriction.
For further information:
Jonas Jönmark, vd, AcuCort AB
Phone: 070 365 5400
E-mail: jonas.jonmark@acucort.se
About AcuCort AB (publ)
AcuCort has developed and is commercializing Zeqmelit®, a new rapidly dissolving oral film placed on the tongue, based on the well-known cortisone substance dexamethasone. The drug is a smart product in a new, innovative, patented, and user-friendly administration form primarily for the treatment of severe and acute allergic reactions, croup in children, nausea and vomiting during chemotherapy, and for the treatment of patients with COVID-19 requiring supplemental oxygen therapy. Zeqmelit® is approved in Sweden, Denmark, Norway, and Finland. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market. Visit www.acucort.se for more information.